27
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema

, , , , , , , , , , & show all
Pages 928-930 | Received 09 Nov 2011, Accepted 19 Jan 2012, Published online: 02 Jan 2014

References

  • Agostoni A, Cicardi M. Hereditary and acquired Cl-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore). 1993;71:206–15.
  • Parish LC. Hereditary angioedema: diagnosis and management—a perspective for the dermatologist. J Am Acad Dermatol. 2011 (Epub).
  • Lock RJ, Gompels MM. Cl-inhibitor deficiencies (hereditary angioedema): where are we with therapies? Curr Allergy Asthma Rep. 2007;7:264-9.
  • Rottem M, Mader R. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis. J Rheumatol. 2010;37(1):209.
  • Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215–28.
  • Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248–57.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.